Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Brodalumab and the Development of Concentration-response Curve of Brodalumab of Psoriasis Patients.
Who is this study for? Patients with moderate-to-severe psoriasis
What treatments are being studied? Brodalumab
Status: Recruiting
Location: See all (7) locations...
Intervention Type: Procedure, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. Within this study we aim to investigate the predictive value of early serum trough levels of brodalumab and determine the therapeutic window of brodalumab in psoriasis patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis
• Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
Locations
Other Locations
Belgium
AZ Sint-Jan
NOT_YET_RECRUITING
Bruges
AZ Maria Middelares
NOT_YET_RECRUITING
Ghent
AZ Sint-Lucas
NOT_YET_RECRUITING
Ghent
University Hospital of Ghent
RECRUITING
Ghent
University Hospital
NOT_YET_RECRUITING
Leuven
Private Practice Dermatology
NOT_YET_RECRUITING
Maldegem
AZ Delta Rembert
NOT_YET_RECRUITING
Torhout
Contact Information
Primary
Jo Lambert, Prof.
jo.lambert@uzgent.be
09 332 22 87
Backup
Lynda Grine, Dr.
lynda.grine@uzgent.be
09 332 22 87
Time Frame
Start Date: 2018-12-14
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 100
Treatments
Experimental: Standard of care - brodalumab
Patients will continue to receive brodalumab according to standard care dosing regimen, i.e. loading dose first (210mg), once a week for 2 weeks (210mg), then a regular dose regimen (210mg) every 2 weeks.
Related Therapeutic Areas
Sponsors
Collaborators: University Ghent, KU Leuven
Leads: University Hospital, Ghent